SCHEMBL13611323

SCHEMBL13611323

CC(OC(=O)c1ccc(N=C=O)cc1)C(=O)OCCOC(=O)C(C)OC(=O)c1ccc(N=C=O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.43
CYP4A11 Q02928 1/20 0.43
ALDH1A1 P00352 2/20 0.40
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA7 P43166 2/20 0.38
CA9 Q16790 2/20 0.38
CA14 Q9ULX7 2/20 0.38
TSHR P16473 3/20 0.38
CYP3A4 P08684 1/20 0.38
SCN1A P35498 1/20 0.36
SCN2A Q99250 1/20 0.36
SCN3A Q9NY46 1/20 0.36
PDCD1 Q15116 1/20 0.36
CD274 Q9NZQ7 1/20 0.36
MAPT P10636 3/20 0.35
RAB9A P51151 3/20 0.35
NPC1 O15118 2/20 0.35
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15375181 0.96 CYP4F2 (0.40) CYP4F2CYP4A11ALDH1A1CA12CA1
SCHEMBL13611330 0.92 CYP4F2 (0.37) CYP4F2CYP4A11ALDH1A1CA12CA1
SCHEMBL13624641 0.91 ADRB2 (0.44) CYP4F2CYP4A11ALDH1A1TSHRMAPT
SCHEMBL14802567 0.89 CYP4F2 (0.36) CYP4F2CYP4A11ALDH1A1CA12CA1
SCHEMBL14763128 0.87 CYP4F2 (0.34) CYP4F2CYP4A11ALDH1A1CA12CA1
SCHEMBL13611325 0.86 NPC1 (0.38) CYP4F2CYP4A11ALDH1A1TSHRCYP3A4
SCHEMBL15908127 0.86 CYP4F2 (0.34) CYP4F2CYP4A11ALDH1A1TSHRMAPT
SCHEMBL16270516 0.84 ELANE (0.43) CYP4F2CYP4A11ALDH1A1CA12CA1
SCHEMBL14802568 0.83 TSHR (0.35) CYP4F2CYP4A11ALDH1A1TSHRCYP3A4
SCHEMBL5797419 0.82 CA12 (0.58) CYP4F2CYP4A11ALDH1A1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11116866-B2 Multi-putty adhesive and cement compositions for tissue hemostasis, repair and reconstruction ABYRX, INC. (US) 2021-09-14 US disclosed
US-20200061236-A1 MULTI-PUTTY ADHESIVE AND CEMENT COMPOSITIONS FOR TISSUE HEMOSTASIS, REPAIR AND RECONSTRUCTION ORTHOCON, INC. 2020-02-27 US disclosed
US-20190099514-A1 MULTI-PUTTY ADHESIVE AND CEMENT COMPOSITIONS FOR TISSUE HEMOSTASIS, REPAIR AND RECONSTRUCTION ORTHOCON, INC. 2019-04-04 US disclosed
US-20160250374-A1 Absorbable Multi-Putty Bone Cements and Hemostatic Compositions and Methods of Use ORTHOCON, INC. 2016-09-01 US disclosed
US-9314547-B2 Absorbable multi-putty bone cements and hemostatic compositions and methods of use ABYRX INC. (US) 2016-04-19 US disclosed
US-20130078300-A1 BIOABSORBABLE POLYMERS FROM BIOABSORBABLE POLYISOCYANATES AND USES THEREOF BEZWADA BIOMEDICAL, LLC (US) 2013-03-28 US disclosed
US-8367747-B2 Bioabsorbable polymers from bioabsorbable polyisocyanates and uses thereof BEZWADA BIOMEDICAL, LLC (US) 2013-02-05 US disclosed
US-8367747-B2 Bioabsorbable polymers from bioabsorbable polyisocyanates and uses thereof BEZWADA BIOMEDICAL, LLC (US) 2013-02-05 US disclosed
US-20090292029-A1 BIOABSORBABLE POLYMERS FROM BIOABSORBABLE POLYISOCYANATES AND USES THEREOF BEZWADA BIOMEDICAL, L.L.C (US) 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090292029-A1 BIOABSORBABLE POLYMERS FROM BIOABSORBABLE POLYISOCYANATES AND USES THEREOF PUF60, PFAS, UROD CYP4F2 691/4885CYP4A11 845/4885ALDH1A1 2465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.